Patents by Inventor Nabil Hanna

Nabil Hanna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant antibodies for human therapy
    Patent number: 5756096
    Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 26, 1998
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Roland A. Newman, Nabil Hanna, Ronald W. Raab
  • Recombinant antibodies for human therapy
    Patent number: 5750105
    Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 12, 1998
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Roland A. Newman, Nabil Hanna, Ronald W. Raab
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Patent number: 5736137
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: April 7, 1998
    Assignee: Idec Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Recombinant antibodies for human therapy
    Patent number: 5693780
    Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignee: Idec Pharmaceuticals Corporation
    Inventors: Roland A. Newman, Nabil Hanna, Ronald W. Raab
  • Recombinant antibodies for human therapy
    Patent number: 5681722
    Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 28, 1997
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Roland A. Newman, Nabil Hanna, Ronald W. Raab
  • Recombinant antibodies for human therapy
    Patent number: 5658570
    Abstract: Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: August 19, 1997
    Assignee: Idec Pharmaceuticals Corporation
    Inventors: Roland A. Newman, Nabil Hanna, Ronald W. Raab
  • Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
    Patent number: 5317019
    Abstract: A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such a human an effective, interleukin-1 production inhibiting amount of a diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead atom wherein said second ring may also contain sulfur, oxygen or an additional nitrogen atom, and may contain additional unsaturation.This invention relates to a method of inhibiting the production of Tumor Necrosis Factor (TNF) by monocytes or macrophages in a human in need thereof which comprises administering to such mammal an effective, TNF production inhibiting amount of a compound of Formula (I) as described herein. The compounds of Formula (II) are generally described as diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead wherein said ring may also contain sulfur, oxygen, or an additional nitrogen atom, and may contain additional unsaturation.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: May 31, 1994
    Assignee: SmithKline Beecham Corp.
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee, Bartholomew J. Votta, Philip L. Simon, Alison M. Badger, Klaus M. Esser
  • Pyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
    Patent number: 5145858
    Abstract: Compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing said compounds, and their use as 5-lipoxygenase pathway inhibitors.
    Type: Grant
    Filed: December 26, 1991
    Date of Patent: September 8, 1992
    Assignee: SmithKline Beecham Corp.
    Inventors: Jerry L. Adams, Paul E. Bender, John G. Gleason, Nabil Hanna, John F. Newton, Jr., Carl D. Perchonock
  • Inhibition of the 5-lipoxygenase pathway
    Patent number: 5134150
    Abstract: A method of inhibiting the 5-lipoxygenase pathway in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a diaryl- substituted imidazole fused to a thiazole pyrrolidine, thiazide or piperidine ring to such animal.
    Type: Grant
    Filed: December 4, 1989
    Date of Patent: July 28, 1992
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul E. Bender, John G. Gleason, Don E. Griswold, Nabil Hanna, Ivan Lantos, Kazys A. Razgaitis, Henry M. Sarau, Susan C. Shilcrat
  • Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
    Patent number: 5002941
    Abstract: Compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing said compounds, and their use as 5-lipoxygenase pathway inhibitors.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: March 26, 1991
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Paul E. Bender, John G. Gleason, Nabil Hanna, John F. Newton, Jr., Carl D. Perchonock, Kazys Razgaitis
  • Inhibition of interleukin-1 production by monocytes and/or macrophages
    Patent number: 4794114
    Abstract: A method of inhibiting the 5-lipoxygenase pathway in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a diaryl-substituted imidazole fused to a thiazole pyrrolidine, thiazide or piperidine ring to such animal.
    Type: Grant
    Filed: June 17, 1987
    Date of Patent: December 27, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
  • Inhibition of interleukin-1 by monocytes and/or macrophages
    Patent number: 4780470
    Abstract: A method of inhibiting the production of interleukin-1 by monocytes in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 4,5-diaryl-2(substituted)imidazole.
    Type: Grant
    Filed: August 19, 1986
    Date of Patent: October 25, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
  • Inhibition of interleukin-1 production by monocytes and/or macrophages
    Patent number: 4778806
    Abstract: A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 2-2'-[1,3-propan-2-onediyl-bis(thio)]bis-1H-imidazole or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 19, 1986
    Date of Patent: October 18, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
  • Inhibition of the 5-lipoxygenase pathway
    Patent number: 4751310
    Abstract: Compounds having the formula ##STR1## wherein n is 0 or 1, R.sup.2 through R.sup.9 are H or C.sub.1-2 alkyl, and X is pyridyl or mono- or disubstituted phenyl are useful in the preparation of the compounds which inhibit the 5-lipoxygenase pathway.
    Type: Grant
    Filed: September 22, 1987
    Date of Patent: June 14, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Nabil Hanna
  • Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
    Patent number: 4719218
    Abstract: A method of inhibiting the production of 5-lipoxygenase products in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a 2(3)-(pyridyl)-3-(2)-substituted phenyl)-6,7-dihydro-[5H]-pyrrolo-[1,2-a]imidazole, a 2(3)-(pyridyl)-3(2)-(substituted phenyl)-5,6,7,8-tetrahydro-imidazo[1,2,-a]pyridine, or a pharmaceutically acceptable salt thereof, to such animal.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: January 12, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Nabil Hanna
  • Inhibition of 5-lipoxygenase products
    Patent number: 4686231
    Abstract: Novel compounds, compositions and pharmaceutical a method of inhibiting the 5-lipoxygenase pathway in an animal in need thereof which comprising administering an effective, 5-lipoxygenase pathway inhibiting amount of a 4,5-diaryl-2(substituted)-imidazole or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: August 11, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, Henry M. Sarau